Qidong Yixin Granule trial, atrial fibrillation ablation, China
Summary
The National Library of Medicine registered a new clinical trial (NCT07508618) on ClinicalTrials.gov evaluating Qidong Yixin Granule in patients undergoing atrial fibrillation ablation in China. The study is listed as sponsored by a Chinese institution. This is a routine registration entry documenting an interventional trial studying an herbal medicine intervention.
What changed
ClinicalTrials.gov has registered a new clinical study (NCT07508618) titled 'Qidong Yixin Granule trial, atrial fibrillation ablation, China.' The trial is an interventional study evaluating the efficacy and safety of Qidong Yixin Granule in patients undergoing atrial fibrillation ablation. The study is conducted in China and registered on the US-based ClinicalTrials.gov database.
Clinical trial sponsors and investigators should continue to ensure proper registration of applicable clinical trials on ClinicalTrials.gov per regulatory requirements. For this specific trial, no immediate compliance deadlines or penalties are specified in the registration record.
Archived snapshot
Apr 3, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Show glossary
Related changes
Get daily alerts for ClinicalTrials.gov
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NLM.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov publishes new changes.